Darigabat

DB18966InvestigationalSmall molecule

Darigabat is under investigation in clinical trial NCT05941442 (A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder).

Mechanism: Pharmacologically active on Gamma-aminobutyric acid receptor subunit alpha-2, Gamma-aminobutyric acid receptor subunit alpha-5, and Gamma-aminobutyric acid receptor subunit alpha-3
Curator reviewed
Formula / weight: C₂₂H₂₁FN₄O₃S · 440.49 g/mol (avg)
Also known as: 7-ethyl-4-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxybiphenyl-3-yl)-7h-imidazo(4,5-c)-pyridazine · 7h-imidazo(4,5-c)pyridazine, 7-ethyl-4-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxy(1,1'-biphenyl)-3-yl)-
Code names: CVL-865 · PF-06372865

Resolves to

Compound

UNIIO9BP19HZ3QCAS1614245-70-3ChEMBLCHEMBL3647536

Structure

InChIKeyPTTQXDBPTFOCMT-UHFFFAOYSA-NSMILESCCN1C=NC2=C(C=NN=C12)C1=CC=C(F)C(=C1)C1=CC=C(C=C1OC)S(=O)(=O)CC

Targets

P47869GABRA2P31644GABRA5P34903GABRA3

What you can answer from here — as of July 09, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Darigabat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account